GlassScriptPhysician profile
Robert J Kraut
NPI 1306861687
$4,718.34
in general payments reported to CMS, 2019-2025
19 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $613 · 2021: $492 · 2022: $478 · 2023: $689 · 2024: $531 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,238.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $914.99 | 2019-2025 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $688.50 | 2019-2021 | |
| Abbvie INC. | $623.58 | 2022-2025 | |
| Astellas Pharma US INC | $571.74 | 2023-2025 | Izervay |
| Genentech USA, INC. | $543.82 | 2019-2025 | Vabysmo, Susvimo |
| Apellis Pharmaceuticals, INC. | $288.88 | 2022-2025 | Syfovre |
| Alimera Sciences, INC. | $261.26 | 2019-2023 | Iluvien |
| Kala Pharmaceuticals, INC. | $177.63 | 2019-2021 | |
| Harrow Eye, LLC | $138.64 | 2024-2025 | Iheezo |
| Regeneron Pharmaceuticals, INC. | $112.85 | 2020 | |
| Allergan, INC. | $95.33 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $75.39 | 2019 | |
| Eyepoint US, INC. | $56.98 | 2019-2022 | |
| Halozyme INC | $54.84 | 2025 | Hylenex Recombinant |
| Coherus Oncology, INC. | $35.68 | 2022-2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $28.17 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.42 | 2021 | |
| Bausch & Lomb Americas INC. | $16.46 | 2023 | Xipere |
| Dompe US, INC. | $15.18 | 2024 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kraut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.